Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Allies With MIT s RNAi Consortium; Will Help Develop, Distribute Reagents

NEW YORK, March 16 (GenomeWeb News) - Sigma-Aldrich has become a "scientific collaborator" and distribution partner to MIT's RNAi Consortium, bringing to four the number of TRC's corporate partners, the company said today.


The TRC's three-year goal is "to create a comprehensive library of RNA Interference reagents designed to reduce expression of specific human and mouse genes, thereby enabling scientists to elucidate the function of the targeted gene," according to a statement.


To that end, Sigma-Aldrich will help the consortium develop and distribute clones, purified DNA, and viral stocks from the group's RNAi libraries to researchers worldwide, the company said.


Based at The Broad Institute, the consortium comprises seven research institutions, including Massachusetts General Hospital, Harvard Medical School, Dana-Farber Cancer Institute, The Broad Institute, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, and Academia Sinica. It is also home to four companies, including Bristol-Myers Squibb, Eli Lilly, Novartis, and now Sigma.


Financial terms of Sigma's participation were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.